A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Whose Tumors Express Low or Negative EGFr Levels of Immunohistochemistry Following Treatment with Fluoropyrimidine, Irinotecan, and Oxalip

Status
Active
Cancer Type
Colon/Rectal Cancer
Trial Phase
Phase II
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT00089635
Protocol IDs
20030250 (primary)
UCLA-0410011-01
AMGEN-20030250
Study Sponsor
Amgen, Incorporated

Summary

The purpose of this study is to determine that ABX-EGF will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy.